| Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on. | |
| | |
MedLine Citation:
|
PMID: 21445929 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
A considerable proportion of liver transplantation recipients who receive hepatitis B immunoglobulin (HBIG) monotherapy for hepatitis B virus (HBV) prophylaxis develop resistance to HBIG. We retrospectively assessed the efficacy of HBV prophylaxis in 1524 patients who received primary high-dose HBIG monotherapy (n = 1463) or with a preemptive antiviral add-on as secondary combination therapy (n = 61). At a median follow-up time of 57 months, 106 (7.3%) patients receiving HBIG monotherapy experienced HBV recurrence, with a 10-year HBV recurrence rate of 9.8%, compared to none of the patients receiving preemptive combination therapy (P = 0.047). Thirteen patients (12.3%) with HBV recurrence failed antiviral therapy, leading to death or retransplantation. Response rates to rescue therapy before and after use of adefovir/entecavir were 44.4% and 91.8%, respectively. Acute exacerbation was not associated with treatment failure, but required prolonged treatment. Of 84 surviving patients with HBV recurrence, 44 (52.4%) showed no evidence of blood HBV DNA. The Gly145Arg mutation was found in 11 of 15 (73.3%) patients, whereas 25 of 71 (35.2%), 2 of 29 (6.9%), and 4 of 8 (50%) patients were resistant to lamivudine, adefovir, and entecavir, respectively. In conclusion, our finding of a 10-year HBV recurrence rate of 9.8% in patients receiving high-dose HBIG monotherapy indicates that this treatment is effective but requires complementary measures. Strict surveillance following HBIG monotherapy is necessary to enhance responses to rescue antiviral therapy. Preemptive conversion to combination therapy has a complementary role in prophylaxis with primary high-dose HBIG monotherapy, especially for patients at high risk of HBV recurrence. Liver Transpl, 2011. © 2011 AASLD. |
| | |
Authors:
|
Shin Hwang; Chul-Soo Ahn; Gi-Won Song; Ki-Hun Kim; Deok-Bog Moon; Heung-Bum Oh; Young-Suk Lim; Han Chu Lee; Tae-Yong Ha; Dong-Hwan Jung; Young-Hwa Chung; Sung-Gyu Lee |
Related Documents
:
|
21541559 - Phase ii pilot trial of preoperative high-dose chemotherapy in patients with malignant ... 1829919 - Phase ii trial of cisplatin for adenocarcinoma of unknown primary site. ikz/iko clinica... 21207029 - A comparison of prognosis between patients with hepatitis b and c virus-related hepatoc... 1312769 - Non-small-cell lung cancer (nsclc): chemotherapy in advanced disease. our experience in... 12588609 - Advanced ureteral cancer with complete remission achieved by taxan containing systemic ... 21286339 - Fibrosis and ast to platelet ratio index predict post-operative prognosis for solitary ... 22966259 - Oral low-dose dexamethasone for androgen-independent prostate cancer patients. 8381999 - Surveillance versus nerve-sparing retroperitoneal lymphadenectomy in stage i nonseminom... 20890789 - Calf survival and reproductive performance of holstein-friesian cows in central ethiopia. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society Volume: 17 ISSN: 1527-6473 ISO Abbreviation: Liver Transpl. Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-03-29 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100909185 Medline TA: Liver Transpl Country: United States |
Other Details:
|
Languages: eng Pagination: 456-65 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 American Association for the Study of Liver Diseases. |
Affiliation:
|
Department of Surgery, Division of Hepatobiliary Surgery and Liver Transplantation, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transp...
Next Document: Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: The first clinica...